Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieron Dunleavy

Showing results (21-30 of 130) with videos related to

Pageof 13
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|December 8, 2020
Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic AdvancesDai Chihara, Kieron Dunleavy
Blood|April 4, 2020
Tackling Burkitt when it's backAron Simkins, Kieron Dunleavy
Seminars in Hematology|March 26, 2015
Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphomaKieron Dunleavy, Christian Steidl
Hematology. American Society of Hematology. Education Program|December 10, 2013
Update on the treatment of HIV-associated hematologic malignanciesRichard F Little, Kieron Dunleavy
Oncology (Williston Park, N.Y.)|May 21, 2014
Appropriate management of molecular subtypes of diffuse large B-cell lymphomaKieron Dunleavy, Wyndham H Wilson
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2025
SOHO State of the Art Updates and Next Questions | Latest Advances in the Management of Primary Mediastinal B-Cell LymphomaCoen J Lap, Kieron Dunleavy
Current Oncology Reports|April 11, 2022
Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic StrategiesMichael R Cook, Kieron Dunleavy
Leukemia & Lymphoma|August 28, 2010
Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphomaKieron Dunleavy, Wyndham H Wilson
Leukemia & Lymphoma|April 25, 2007
Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategyKieron Dunleavy, Wyndham H Wilson
Blood|December 16, 2014
Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?Kieron Dunleavy, Wyndham H Wilson
Pageof 13

Showing results (21-30 of 130) with videos related to

Sort By:
Pageof 13
Clinical Lymphoma, Myeloma & Leukemia|December 8, 2020
Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic AdvancesDai Chihara, Kieron Dunleavy
Blood|April 4, 2020
Tackling Burkitt when it's backAron Simkins, Kieron Dunleavy
Seminars in Hematology|March 26, 2015
Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphomaKieron Dunleavy, Christian Steidl
Hematology. American Society of Hematology. Education Program|December 10, 2013
Update on the treatment of HIV-associated hematologic malignanciesRichard F Little, Kieron Dunleavy
Oncology (Williston Park, N.Y.)|May 21, 2014
Appropriate management of molecular subtypes of diffuse large B-cell lymphomaKieron Dunleavy, Wyndham H Wilson
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2025
SOHO State of the Art Updates and Next Questions | Latest Advances in the Management of Primary Mediastinal B-Cell LymphomaCoen J Lap, Kieron Dunleavy
Current Oncology Reports|April 11, 2022
Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic StrategiesMichael R Cook, Kieron Dunleavy
Leukemia & Lymphoma|August 28, 2010
Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphomaKieron Dunleavy, Wyndham H Wilson
Leukemia & Lymphoma|April 25, 2007
Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategyKieron Dunleavy, Wyndham H Wilson
Blood|December 16, 2014
Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?Kieron Dunleavy, Wyndham H Wilson
Pageof 13